Epstein Barr Virus Positivity and Behavioral Patterns in Nasopharyngeal Cancer Patients Presenting in Oncology Ward at JPMC, Karachi

Epstein Barr Virus Positivity in Nasopharyngeal Cancer Patients

Authors

  • Sana Nasir Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Ghulam Haider Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Mehwish Jabeen Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Zubair Mughis Department of Cardiac Surgery, Pakistan Navy Station Shifa Hospital, Karachi, Pakistan
  • Tuba Babar Khan Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Saima Zahoor Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Ahra Sami Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Berkha Rani Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • Sana Sehar Department of Medical Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i12.2072

Keywords:

Nasopharyngeal Cancer, Epstein-Barr Virus, Clinical Stage, Latent Membrane Protein

Abstract

Immunohistochemistry tests for the presence of the Epstein-Barr virus latent membrane protein (EBV-LMP), which can be used to diagnose non-Hodgkin's lymphoma. Tumors expressing high amounts of latent membrane protein 1 (LMP-1) provide more evidence that EBV is an etiologic agent in the development of non-Hodgkin lymphoma. Objective: To investigate the association between Epstein-Barr Virus infection and Nasopharyngeal Cancers within a cohort of 131 patients. Methods: A prospective, observational approach was employed, gathering demographic data, addiction profiles, clinical stages, histopathological types, and Epstein-Barr Virus status through patient interviews and medical records review. Polymerase chain reaction assisted in the detection of the Epstein Barr Virus in paraffin-embedded tissue slices that had been treated with formalin. Results: Among the participants, 92 (70.2%) tested positive for Epstein-Barr Virus infection. Notably, 49.6% of Epstein-Barr Virus-positive individuals were active smokers, and 64.9% were treatment-naive. Epstein-Barr Virus positivity was prevalent in stage II (40.5%) and stage III (35.1%) nasopharyngeal cancer patients. Conclusions: It was concluded that understanding the role of the Epstein-Barr Virus and associated risk factors in nasopharyngeal cancer development is crucial for targeted interventions and preventive measures. Further research could enhance our understanding of Epstein-Barr Virus-associated cancers and inform prospective intervention methods.

References

Salahuddin S, Khan J, Azhar J, Whitehurst CB, Qadri I, Shackelford J et al. Prevalence of Epstein–Barr Virus Genotypes in Pakistani Lymphoma Patients. Asian Pacific Journal of Cancer Prevention. 2018; 19(11): 3153. doi: 10.31557/APJCP.2018.19.11.3153.

Chan AT, Hui EP, Ngan RK, Tung SY, Cheng AC, Ng WT et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology. 2018 Nov; 36(31): 3091-100. doi: 10.1200/JCO.2018.77.7847.

Salano VE, Mwakigonja AR, Abdulshakoor A, Kahinga AA, Richard EM. Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma. Journal of Global Oncology. 2021 Sep; 7: 1406-12. doi: 10.1200/GO.21.00120.

Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019; 394(1):64–80. doi: 10.1016/S0140-6736(19)30956-0

Tsang CM, Lui VW, Bruce JP, Pugh TJ, Lo KW. Translational Genomics of Nasopharyngeal Cancer. In Seminars in Cancer Biology. 2020 Apr; 61: 84-100. doi: 10.1016/j.semcancer.2019.09.006.

Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus neoplasia. Am J Pathol. 1995;146(6):1355–1367.

Ayee R, Ofori ME, Tagoe EA, Languon S, Searyoh K, Armooh L et al. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana. Viruses. 2020 Jul; 12(7): 766. doi: 10.3390/v12070766.

Xuemei J, Weidong Z, Conghua X, Bicheng W, Gong Z, Fuxiang Z. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer. 2011;129(3):724–732.doi:10.1002/ijc.25696

Ruuskanen M, Irjala H, Minn H, Vahlberg T, Randen‐Brady R, Hagström J et al. Epstein‐Barr Virus and Human Papillomaviruses as Favorable Prognostic Factors in Nasopharyngeal Carcinoma: A Nationwide Study in Finland. Head & Neck. 2019 Feb; 41(2): 349-57. doi: 10.1002/hed.25450

Rafiq F, Rehman A, Khan AA. Clinical Presentation of Nasopharyngeal Carcinoma Experience at ENT Department, Jinnah Hospital, Lahore. Headache. 2018 Jul; 15: 30.

Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM et al. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. Journal of Virology. 2017 Nov; 91(21): 10-128. doi: 10.1128/JVI.00382-17.

Sharif SE, Zawawi N, Yajid AI, Shukri NM, Mohamad I. Pathology Classification of Nasopharyngeal Carcinoma. In an Evidence-Based Approach to the Management of Nasopharyngeal Cancer. 2020 Jan: 73-92. doi: 10.1016/B978-0-12-814403-9.00005-7.

Fierti AO, Yakass MB, Okertchiri EA, Adadey SM, Quaye O. The Role of Epstein-Barr Virus in Modulating Key Tumor Suppressor Genes in Associated Malignancies: Epigenetics, Transcriptional, And Post-Translational Modifications. Biomolecules. 2022 Jan; 12(1): 127. doi: 10.3390/biom12010127.

Chan JY and Wong ST. The Role of Plasma Epstein‐Barr Virus DNA in the Management of Recurrent Nasopharyngeal Carcinoma. The Laryngoscope. 2014 Jan; 124(1): 126-30. doi: 10.1002/lary.24193.

Su ZY, Siak PY, Leong CO, Cheah SC. The Role of Epstein–Barr Virus in Nasopharyngeal Carcinoma. Frontiers in Microbiology. 2023 Feb; 14: 1116143. doi: 10.3389/fmicb.2023.1116143.

Wu L, Li C, Pan L. Nasopharyngeal Carcinoma: A Review of Current Updates. Experimental and Therapeutic Medicine. 2018 Apr; 15(4): 3687-92. doi: 10.3892/etm.2018.5878.

Vasudevan HN and Yom SS. Nasopharyngeal Carcinoma and Its Association with Epstein-Barr Virus. Hematology/Oncology Clinics. 2021 Oct; 35(5): 963-71. doi: 10.1016/j.hoc.2021.05.007.

Al-Anazi AE, Alanazi BS, Alshanbari HM, Masuadi E, Hamed ME, Dandachi I et al. Increased Prevalence of EBV Infection in Nasopharyngeal Carcinoma Patients: A Six-Year Cross-Sectional Study. Cancers. 2023 Jan; 15(3): 643. doi: 10.3390/cancers15030643.

Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK et al. Targeting Epstein-Barr virus in Nasopharyngeal Carcinoma. Frontiers in Oncology. 2020 May; 10: 600. doi: 10.3389/fonc.2020.00600.

Leong MM and Lung ML. The Impact of Epstein-Barr Virus Infection on Epigenetic Regulation of Host Cell Gene Expression in Epithelial and Lymphocytic Malignancies. Frontiers in Oncology. 2021 Feb; 11: 629780. doi: 10.3389/fonc.2021.629780.

Downloads

Published

2024-12-31
CITATION
DOI: 10.54393/pjhs.v5i12.2072
Published: 2024-12-31

How to Cite

Nasir, S., Haider, G., Jabeen, M., Mughis, Z., Babar Khan, T., Zahoor, S., Sami, A., Rani, B., & Sehar, S. (2024). Epstein Barr Virus Positivity and Behavioral Patterns in Nasopharyngeal Cancer Patients Presenting in Oncology Ward at JPMC, Karachi: Epstein Barr Virus Positivity in Nasopharyngeal Cancer Patients. Pakistan Journal of Health Sciences, 5(12), 151–156. https://doi.org/10.54393/pjhs.v5i12.2072

Issue

Section

Original Article

Plaudit

Most read articles by the same author(s)